Any current/future new fundraising through debt or equity?

Rossari Biotech's current capex is mostly funded through a mix of internal accruals and debt. The company is not averse to raising further debt if needed to fund expansions. Large capex projects are spread over time, allowing manageable funding. There are no specific mentions of planned equity fundraising in the near term. The company retains strong liquidity and conservative leverage with headroom to support growth. Future strategic opportunities, including large projects in India and internationally, may trigger funding decisions. Overall, the approach is phased, prudent debt usage with inte

Any current/future capex/capital investment/strategic investment?

Rs. 97 crore and Rs. 95 crore capex announced last quarter, expected to come on stream in FY27 via 5-6 projects in a phased manner. Capacity to reach approximately 385,000 tons by FY26 end. New ethoxylation capacity commissioned at Unitop (15,000 tons) and Dahej (20,000 tons) confirmed; part of ongoing expansions. Total planned capital outlay of Rs. 192 crore nearing completion; remaining projects to be commissioned in coming months. Board approved up to USD 8 million investment in wholly owned subsidiary in Saudi Arabia (Rossari International Limited Company) for feasibility and expansion stu

Future growth expectations in sales/revenue/volumes?

Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN). Exports grew robustly by 36% YoY in Q2 and 27% in H1, now comprising nearly 28% of total revenue, with growth driven by new geographies like Far East, Southeast Asia, and MENA. Capacity expansions (total planned Rs. 192 crore capex) including 20,000 MT at Dahej and 15,000 MT ethoxylation at Unitop will support future revenue growth. Capex projects expected to deliver 3-4x asset turns at full utilization, with peak utilization by FY28. Non-EO and new product portfolios (app

Future growth expectations in earnings/operating earnings/profits/EPS?

Rossari expects steady volume-driven revenue growth with exports rising robustly (36% YoY in Q2), supported by product portfolio expansion and new capacities. EBITDA margins are expected to remain stable, with core B2B margins in the 14%-16% range excluding consumer and institutional businesses. Profitability is anticipated to strengthen progressively as new business initiatives and capacity expansions ramp up, particularly from FY27 onwards. Significant capex completed and underway (Rs. 192 crore total), expected to deliver 3-4x asset turns at full utilization by FY28. New ethoxylation capaci

IN US

Sale is live|00:00:00left today

Rossari Biotech LtdQ3 FY25Chemicals & Petrochemicals

Rossari Biotech Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 18.8Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN).
→Exports grew robustly by 36% YoY in Q2 and 27% in H1, now comprising nearly 28% of total revenue, with growth driven by new geographies like Far East, Southeast Asia, and MENA.
→Capacity expansions (total planned Rs. 192 crore capex) including 20,000 MT at Dahej and 15,000 MT ethoxylation at Unitop will support future revenue growth.
→Capex projects expected to deliver 3-4x asset turns at full utilization, with peak utilization by FY28.
→Non-EO and new product portfolios (approx. 50 new products in pipeline) expected to ramp up gradually.
→Institutional and B2C verticals currently soft but losses are reducing; expected to scale meaningfully over time.
→Guidance: Core B2B EBITDA margins stable at 14%-16%, with volume-driven growth continuing.
→Phased capacity additions scheduled during FY27 and beyond will support incremental sales growth.

Margin guidance

Category 3

→Rossari expects steady volume-driven revenue growth with exports rising robustly (36% YoY in Q2), supported by product portfolio expansion and new capacities.
→EBITDA margins are expected to remain stable, with core B2B margins in the 14%-16% range excluding consumer and institutional businesses.
→Profitability is anticipated to strengthen progressively as new business initiatives and capacity expansions ramp up, particularly from FY27 onwards.
→Significant capex completed and underway (Rs. 192 crore total), expected to deliver 3-4x asset turns at full utilization by FY28.
→New ethoxylation capacity and non-EO product pipelines should contribute to margin improvement and higher earning potential.
→Institutional and consumer verticals are improving operational efficiency, with reduced losses indicating future profit growth potential.
→Overall, stable margins with increasing absolute profits aimed from FY27, aligned with capacity utilization and improved product mix.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Rossari Biotech's current capex is mostly funded through a mix of internal accruals and debt.
→The company is not averse to raising further debt if needed to fund expansions.
→Large capex projects are spread over time, allowing manageable funding.
→There are no specific mentions of planned equity fundraising in the near term.
→The company retains strong liquidity and conservative leverage with headroom to support growth.
→Future strategic opportunities, including large projects in India and internationally, may trigger funding decisions.
→Overall, the approach is phased, prudent debt usage with internal cash flow backing, and no immediate plans for equity fundraising disclosed.

Order book

- The transcript does not provide specific details or figures about the current or expected order book or pending orders. - However, there is mention of growing export momentum and revenue ramp-up expected every quarter, especially from non-EO business, depending on market conditions. - The company is focusing on emerging geographies such as Far East, Southeast Asia, and MENA regions to sustain or increase export sales momentum. - There is also ongoing capacity expansion and commissioning aimed to support future growth. - Uncertainty in global markets, especially tariffs affecting exports (notably to the US), is impacting order visibility and customer behavior. - Management remains hopeful for order growth as new products and capacities come online despite challenges. No specific numeric order book data or pending orders were disclosed in the call transcript.

Capex plans

Yes

→Rs. 97 crore and Rs. 95 crore capex announced last quarter, expected to come on stream in FY27 via 5-6 projects in a phased manner.
→Capacity to reach approximately 385,000 tons by FY26 end.
→New ethoxylation capacity commissioned at Unitop (15,000 tons) and Dahej (20,000 tons) confirmed; part of ongoing expansions.
→Total planned capital outlay of Rs. 192 crore nearing completion; remaining projects to be commissioned in coming months.
→Board approved up to USD 8 million investment in wholly owned subsidiary in Saudi Arabia (Rossari International Limited Company) for feasibility and expansion studies.
→Small capex underway in Southeast Asia (Thailand) for a blending unit.
→Additional planned capacity expansions are staggered to manage balance sheet and leverage prudently.
→Asset turn from new capex expected around 4x at peak utilization, with revenue potential of approx. Rs. 3,500 crore from new capacities.

How does Rossari Biotech Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Rossari Biotech Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Rossari Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio